Key Takeaways
“It is my job to recognize where our actions can have the greatest impact,” CDC Director Rochelle P. Walensky, MD, MPH said in a press statement.
Under the new designation, the CDC now recommends a third Pfizer shot for people over 65, residents in long-term care facilities, all adults who have underlying medical conditions, and people who are at occupational risk of COVID-19 transmission such as healthcare workers and teachers.
The Advisory Committee on Immunization Practices (ACIP), a CDC panel, had excluded frontline workers from the booster campaign in a 9-to-6 vote. The decision received heavy backlash from healthcare groups and advocates, who stressed the need for additional protection among first responders.
National Nurses United (NNU), the largest union of registered nurses, condemned the ACIP’s vote, noting that healthcare workers are at high risk of exposure to the COVID-19 virus.
“It is unconscionable that ACIP would not vote to keep us safer from death, severe COVID, and long COVID,” NNU President Deborah Burger, RN said in apress release. “Leaving healthcare workers out is akin to early CDC guidance telling nurses that a bandana is sufficient protection while caring for a patient with COVID-19.”
What This Means For YouThe CDC recommends Pfizer booster shots for people who received an initial series of Pfizer and are:65 or olderresidents in long-term care facilities18 and older and with underlying medical condition18 and older and at occupational risk of COVID-19 transmission, such as healthcare workers and teachers
What This Means For You
The CDC recommends Pfizer booster shots for people who received an initial series of Pfizer and are:65 or olderresidents in long-term care facilities18 and older and with underlying medical condition18 and older and at occupational risk of COVID-19 transmission, such as healthcare workers and teachers
The CDC recommends Pfizer booster shots for people who received an initial series of Pfizer and are:
“We applaud this bold decision-making that prioritizes the health and safety of workers on the front lines of this ongoing crisis, and we know that her decision will absolutely save lives,” Burger said.
Most People May Still Need a Booster Shot Later
Jonathan Baktari, MD, CEO of e7health, says the decision to approve or withhold boosters from certain populations has to do primarily with the logistics of a vaccine rollout and public health discussions. He adds that the CDC’s change reflects the agency’s struggle to balance a booster rollout while figuring out how to combat vaccine hesitancy for the initial series.
“It’s pretty clear from the studies that it’s just a matter of time before everybody’s going to need a booster,” Baktari tells Verywell. “Why it’s so muddy is because they’re struggling with how to phase it in. I think in three months, all of these minor nuances will be less important.”
As studies show that antibodies from the mRNA vaccines declined after around six months,it’s only a matter of time before boosters will be available to the general population, he adds.
“Today’s booster could be tomorrow’s three-shot series, potentially,” Baktari says.
He adds that the main purpose of boosters is to strengthen an individual’s immune system. Whether or not boosters can also reduce community transmission of COVID-19 is understudied and unclear, he says.
CDC Study Confirms That COVID-19 Vaccines Block Transmission In the Real World
The ACIP panelists who voted against approving boosters for frontline workers argued that the recommendation was too broad and could falsely imply the initial series of the vaccines were not working as is. Some said they worried too broad of an approval could distract the agency from its top priority, which is to make sure as many people as possible are vaccinated.
Baktari says he doubts the booster rollout will change people’s vaccine decisions. Not much will convince the “remaining large portion of the vaccine hesitancy group,” he adds.
Some panelistsexpressed equity concerns about the booster rollout, as the current recommendation only applies to people who received an initial series of Pfizer’s vaccine. From a public health standpoint, Baktari says the rollout may be more successful if the vaccines were authorized simultaneously. He expects the designation can create awkwardness and confusion among providers and recipients.
But it’s unclear how closely these CDC guidelines will be followed. Panelists at ACIP’s meeting noted that some people from unapproved groups have already sought out and received boosters sincethe White House announced its booster plan in August.
“I’ll be curious to see how the frontline people handing out the vaccines address that,” Baktari says.
What Should You Do if You Get a Breakthrough COVID Infection?
The information in this article is current as of the date listed, which means newer information may be available when you read this. For the most recent updates on COVID-19, visit ourcoronavirus news page.
1 SourceVerywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Naaber P, Tserel L, Kangro K et al.Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study.The Lancet Regional Health - Europe. 2021:100208. doi:10.1016/j.lanepe.2021.100208
1 Source
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Naaber P, Tserel L, Kangro K et al.Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study.The Lancet Regional Health - Europe. 2021:100208. doi:10.1016/j.lanepe.2021.100208
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
Naaber P, Tserel L, Kangro K et al.Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study.The Lancet Regional Health - Europe. 2021:100208. doi:10.1016/j.lanepe.2021.100208
Meet Our Medical Expert Board
Share Feedback
Was this page helpful?Thanks for your feedback!What is your feedback?OtherHelpfulReport an ErrorSubmit
Was this page helpful?
Thanks for your feedback!
What is your feedback?OtherHelpfulReport an ErrorSubmit
What is your feedback?